Novel Therapies for CTCL - Andrei Shustov, MD

3 Görünümler
administrator
administrator
08/09/23

Overview of therapy options for cutaneous lymphoma from the CLF's Patient Educational Forum in Seattle, WA on March 1, 2014. Presenter: Andrei Shustov, MD, University of Washington, Fred Hutchinson Cancer Research Center

  • kategori

Daha fazla göster
0 Yorumlar Göre sırala

    Hiçbir yorum bulunamadı

    Facebook Yorumları

    Bir sonraki

    Testing anti-amyloid therapies in preclinical Alzheimer's disease
    00:02:49
    Testing anti-amyloid therapies in preclinical Alzheimer's disease
    administrator
    2 Görünümler
    Dr. David Bartlett - Regional Therapies 2015
    00:01:43
    Dr. David Bartlett - Regional Therapies 2015
    administrator
    2 Görünümler
    Jerry Lewandowski - Regional Cancer Therapies 2015 (Part 2)
    00:05:09
    Jerry Lewandowski - Regional Cancer Therapies 2015 (Part 2)
    administrator
    1 Görünümler
    Cutaneous Lymphoma Treatment Series - Video 4: Systemic Therapies
    00:05:59
    Cutaneous Lymphoma Treatment Series - Video 4: Systemic Therapies
    administrator
    5 Görünümler
    Do People of Color Have an Earlier Onset of CTCL? (Chapter 8)
    00:03:06
    Do People of Color Have an Earlier Onset of CTCL? (Chapter 8)
    administrator
    3 Görünümler
    CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
    00:02:51
    CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
    administrator
    2 Görünümler
    The Importance of Collaboration in Treating CTCL (Chapter 7)
    00:02:30
    The Importance of Collaboration in Treating CTCL (Chapter 7)
    administrator
    3 Görünümler
    The CTCL diagnosis journey
    00:00:20
    The CTCL diagnosis journey
    administrator
    6 Görünümler
    Unmet needs for late-stage CTCL
    00:01:10
    Unmet needs for late-stage CTCL
    administrator
    3 Görünümler
    Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
    00:01:16
    Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
    administrator
    3 Görünümler
    Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
    00:01:35
    Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
    administrator
    4 Görünümler
    FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
    00:08:49
    FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
    administrator
    10 Görünümler
    Pre-clinical activity of tipifarnib in CTCL
    00:02:12
    Pre-clinical activity of tipifarnib in CTCL
    administrator
    5 Görünümler
    Cerdulatinib yields 'encouraging' results in CTCL, PTCL
    00:04:47
    Cerdulatinib yields 'encouraging' results in CTCL, PTCL
    administrator
    4 Görünümler
    CTCL 06 2017
    02:28:08
    CTCL 06 2017
    administrator
    2 Görünümler
    Brentuximab vedotin for CTCL
    00:02:30
    Brentuximab vedotin for CTCL
    administrator
    2 Görünümler
    Clonal evolution in patients with CTCL
    00:02:24
    Clonal evolution in patients with CTCL
    administrator
    3 Görünümler
    RESMAIN: HDAC inhibitor resminostat for CTCL
    00:01:23
    RESMAIN: HDAC inhibitor resminostat for CTCL
    administrator
    2 Görünümler
    Etiopathogenesis of CTCL for dermatology residents I Dr.P.Ram Sushruth
    00:13:18
    Etiopathogenesis of CTCL for dermatology residents I Dr.P.Ram Sushruth
    administrator
    2 Görünümler